PHARMA 7081 Share Price
RM1.16
klse: Pharmaniaga Berhad
Stock Information
Board : Main
Shariah : Shariah Compliant
Sector : Pharmaceuticals Logistic Services Healthcare Products
Address: No. 7, Lorong Keluli 1B, Kawasan Perindustrian Bukit Raja Selatan, Seksyen 7, 40000 Shah Alam, Selangor
Contact: +603-33429999
Website: https://www.pharmaniaga.com/
Stock Background
Pharmaniaga Berhad is an investment holding company. The Company, through its subsidiaries, manufactures, markets, and distributes pharmaceutical and medical products to government hospitals and private institutions. Pharmaniaga also provides web portal services for online trading of health care products.
Profit Analysis: PHARMA 7081
|
Result
Quarter Report History
| Date | Revenue,k | PBT,k | Net Profit,k |
|---|---|---|---|
| 18/05/26 | 1,178,524 | 46,410 | 31,471 |
| 23/02/26 | 938,277 | 11,443 | 7,695 |
| 13/11/25 | 1,007,263 | 10,357 | 7,276 |
| 26/08/25 | 926,864 | 7,434 | 3,960 |
| 07/05/25 | 1,055,349 | 45,503 | 29,579 |
| 28/02/25 | 926,442 | 13,317 | 2,347 |
| 26/11/24 | 1,029,822 | 138,485 | 101,032 |
| 21/08/24 | 838,256 | 3,334 | 2,797 |
| 27/05/24 | 964,959 | 39,044 | 25,646 |
| 29/02/24 | 789,807 | -22,099 | -32,721 |
| 29/11/23 | 885,486 | -56,259 | -49,339 |
| 11/08/23 | 848,734 | 6,342 | 1,961 |
Fundamental
Fundamental Analysis
| Last 4 Quarter Revenue (RM’000) | 4,051 |
|---|---|
| Last 4 Quarter Net Profit (RM’000) | 52,626 |
| Last 4 Quarter EPS (sen) | 1.24 |
| Last 4 Quarter PER | 28.91 |
| Last 4 Quarter Dividend (sen) | 25.00 |
| Last 4 Quarter Dividend Yield (%) | 0.22 |
| Net Tangible Assets (RM) | 0.07 |
| Goodwill (RM) | 151,230 |
| Cash (RM’000) | 258,570 |
| Debt (RM’000) | 819,790 |
| Total Debt (RM’000) | 1,810,000 |
| Net Assets (RM’000) | 434,470 |
| Current Ratio | 0.91 |
| Quick Ratio | 0.46 |
| Cash Ratio | 0.16 |
Technical
Technical Analysis
| MACD (26 vs 12) | -3.648 |
|---|---|
| Exponential Moving Average 5 | 1.164 |
| Exponential Moving Average 20 | 1.169 |
| Exponential Moving Average 90 | 0.824 |
| Relative Strength Index 14 | 0.46 |
| Stochastic %D 3 | 0.32 |
| Stochastic %K 14 | 0.40 |
20 reviews for PHARMA 7081
Show all Most Helpful Highest Rating Lowest Rating
Only logged in customers who have purchased this product may leave a review.
Stock Profit Analysis
-
BNASTRA 7195 ★★★★★RM2.14 - PETRONM 3042 ★★★★★RM3.44
- CMSB 2852 ★★★★★RM1.00
- SUNREIT 5176 ★★★★★RM2.23
Salary Proof
BURSA MALAYSIA –
The Group recorded a loss before tax of RM581 million in 2022 on the back of RM3.5 billion in revenue. It is worth noting that our revenue has remained higher than our pre-pandemic 2019 revenue of RM2.8 billion. Moving forward, the goal is to diversify their business. To achieve this, the group are exploring non-concession healthcare opportunities and expanding their logistics business. Furthermore, the group are pursuing global and regional ventures in order to maintain and expand their presence in private and international markets. The group aim to solidify their position as a leader in the healthcare industry and achieve sustainable growth over the long term.
BURSA MALAYSIA –
In comparison with the immediate preceding quarter, the Group registered a 21.5% higher revenue of RM924.7 million for the quarter under review, largely due to higher contributions from the concession, non-concession and Indonesia businesses. Hence, the Group’s PBT increased more than twofold to RM15.6 million in the quarter under review from RM4.5 million in the immediate preceding quarter.
BURSA MALAYSIA –
The Group registered 20.9% lower revenue of RM761.1 million in the quarter under review, largely due to lower contributions from the concession and Indonesia businesses as a result of the festive season. Hence, the Group’s PBT declined 87.9% to RM4.5 million in the quarter under review from RM37.4 million in the immediate preceding quarter.
BURSA MALAYSIA –
The Group registered 35% higher revenue of RM962 million for the current quarter, largely due to higher contribution from concession and Indonesia businesses. However, the Group’s PBT declined 70% to RM37 million from RM125 million in the immediate preceding quarter. This was mainly attributable to the lower contribution from the sales of the Sinovac COVID-19 Vaccine during the quarter under review.
BURSA MALAYSIA –
The Group registered lower revenue of RM712 million for the current quarter, largely due to lower sales of Sinovac COVID-19 vaccines to MOH. Despite the lower revenue, the Group’s PBT rose 27% to RM125 million from RM98 million in the immediate preceding quarter as a result of lower selling and distribution expenses and other operating expenditure recorded in the quarter under review. Correspondingly, the Group’s PAT for the quarter under review increased 69% to RM85 million from RM50 million in the immediate preceding quarter.
BURSA MALAYSIA –
The Group recorded a higher revenue of RM2.1 billion for the current quarter. This was primarily attributable to the sales of the Sinovac COVID-19 Vaccine to MOH and private sector. Correspondingly, the Group recorded a higher PBT of RM98 million compared with RM22 million in the immediate preceding quarter